Predicting the success of the entire drug discovery process using an evidence-based approach at the start of development…
You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
Everyone knows it’s hard to get regulatory approval for a new drug; getting payer approval is becoming equally difficult. The key to success is building a robust evidence package and understanding how regulators and payers will assess your product.
Evidence reviews — whether they’re informal, addressing such early-stage objectives as trial design, or comprehensive, as for an HTA submission — can make sure a company knows all it should know and all it can know about a drug throughout its lifecycle.
Early Planning & Modelling
Regulatory & Payer Submissions